A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,875,014 shares of TVTX stock, worth $36.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,875,014
Previous 2,203,814 14.92%
Holding current value
$36.7 Million
Previous $18.1 Million 44.8%
% of portfolio
0.04%
Previous 0.03%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.89 - $15.21 $2.59 Million - $5 Million
-328,800 Reduced 14.92%
1,875,014 $26.2 Million
Q2 2024

Aug 09, 2024

SELL
$5.26 - $8.28 $3.46 Million - $5.45 Million
-658,200 Reduced 23.0%
2,203,814 $18.1 Million
Q1 2024

May 13, 2024

SELL
$7.18 - $9.82 $1.57 Million - $2.15 Million
-219,000 Reduced 7.11%
2,862,014 $22.1 Million
Q4 2023

Feb 13, 2024

BUY
$5.44 - $9.5 $5.91 Million - $10.3 Million
1,086,892 Added 54.5%
3,081,014 $27.7 Million
Q3 2023

Nov 14, 2023

BUY
$7.64 - $17.25 $3.35 Million - $7.57 Million
439,109 Added 28.24%
1,994,122 $17.8 Million
Q2 2023

Aug 11, 2023

SELL
$15.3 - $22.61 $9.02 Million - $13.3 Million
-589,809 Reduced 27.5%
1,555,013 $23.9 Million
Q1 2023

May 12, 2023

BUY
$17.82 - $22.89 $9.82 Million - $12.6 Million
551,300 Added 34.6%
2,144,822 $48.2 Million
Q4 2022

Feb 13, 2023

BUY
$18.47 - $26.14 $1.59 Million - $2.25 Million
86,100 Added 5.71%
1,593,522 $33.5 Million
Q3 2022

Nov 14, 2022

SELL
$22.91 - $28.63 $3.43 Million - $4.28 Million
-149,600 Reduced 9.03%
1,507,422 $37.1 Million
Q2 2022

Aug 12, 2022

BUY
$20.94 - $30.01 $6.28 Million - $8.99 Million
299,700 Added 22.08%
1,657,022 $40.2 Million
Q1 2022

May 13, 2022

BUY
$23.61 - $30.6 $7.49 Million - $9.71 Million
317,400 Added 30.52%
1,357,322 $35 Million
Q4 2021

Feb 11, 2022

SELL
$24.34 - $31.17 $4.88 Million - $6.25 Million
-200,496 Reduced 16.16%
1,039,922 $32.3 Million
Q3 2021

Nov 12, 2021

SELL
$12.98 - $25.03 $6.11 Million - $11.8 Million
-470,904 Reduced 27.52%
1,240,418 $30.1 Million
Q2 2021

Aug 13, 2021

BUY
$14.11 - $26.4 $1.73 Million - $3.24 Million
122,600 Added 7.72%
1,711,322 $25 Million
Q1 2021

May 13, 2021

SELL
$23.37 - $31.77 $6.37 Million - $8.66 Million
-272,700 Reduced 14.65%
1,588,722 $39.7 Million
Q4 2020

Feb 10, 2021

BUY
$19.17 - $27.87 $35.7 Million - $51.9 Million
1,861,422 New
1,861,422 $50.7 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.26B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.